Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02533973
Other study ID # LP0076-1079
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date September 2015
Est. completion date March 6, 2018

Study information

Verified date November 2018
Source LEO Pharma
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A phase 4 trial comparing the safety and efficacy of treatment with Xamiol® gel (calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate)) once daily (as required) with Daivonex® scalp solution (calcipotriol 50 mcg/g) twice daily (as required) in Chinese subjects with scalp psoriasis


Recruitment information / eligibility

Status Completed
Enrollment 951
Est. completion date March 6, 2018
Est. primary completion date March 6, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Signed and dated informed consent has been obtained.

2. Subjects of either gender 18 years of age or above.

3. At visit 1, a clinical diagnosis of scalp psoriasis which is:

- of an investigator's assessment of clinical signs of the scalp of at least = 2 in one of the clinical signs, redness, thickness, and scaliness, and at least 1 in each of the other two clinical signs, and total score = 4

- of an extent of 10% or more of the total scalp area

- of at least mild severity according the investigator's global assessment

4. Clinical signs of psoriasis vulgaris on trunk and/or limbs, or subject earlier diagnosed with psoriasis vulgaris on trunk and/or limbs.

5. Female of childbearing potential using a reliable method of contraception for at least 1 month before the trial start and during the course of the trial (e.g., oral contraceptive pill, intrauterine device, contraceptive patches, implantable contraception, condoms) or females of non-childbearing potential (i.e. postmenopausal (absence of menstrual bleeding for 2 years), hysterectomy, bilateral ovariectomy, or tubal section/ligation).

Exclusion Criteria:

1. Current diagnosis of guttate, erythrodermic, exfoliative, or pustular psoriasis.

2. Subjects with any of the following conditions present on the scalp area: viral lesions, fungal and bacterial skin infections, parasitic infections, skin manifestations in relation to syphilis or tuberculosis, rosacea, acne vulgaris, acne rosacea, atrophic skin, striae atrophicae, fragility of skin veins, ichthyosis, ulcers, and wounds.

3. Systemic treatment with biological therapies, whether marketed or not, with a possible effect on psoriasis vulgaris within the following time periods prior to randomisation and during the trial:

- etanercept (Yisaipu) - within 4 weeks prior to randomisation

- infliximab (Remicade) - within 2 months prior to randomisation

- other products: within 4 weeks/5 half-lives (whichever is longer) prior to randomisation

4. Systemic treatment with all other therapies with a possible effect on psoriasis vulgaris (e.g., corticosteroids, retinoids, methotrexate, ciclosporin and other immunosuppressant's, TCM [(traditional Chinese Medicine)]) within 4 weeks prior to randomisation or during the trial.

5. PUVA therapy within 4 weeks prior to randomisation or during the trial.

6. UVB therapy within 2 weeks prior to randomisation or during the trial.

7. Therapies within 2 weeks prior to randomisation and during the trial:

- Topical treatment of body psoriasis with very potent (WHO group IV) corticosteroids

- Topical treatment of face psoriasis with potent or very potent (WHO group III and IV) corticosteroids

- Any topical treatment of the scalp (except for non-steroid medicated shampoos and emollients)

8. Known or suspected renal insufficiency or hepatic disorders or severe heart disease.

9. Clinical signs or symptoms of Cushing's disease or Addison's disease.

10. Known or suspected hypersensitivity to component(s) of IMPs

11. Current participation in any other interventional clinical trial

12. Subjects who have received treatment with any non-marketed drug substance (i.e. an agent which has not yet been made available for clinical use following registration) within 4 weeks/5 half-lives (whichever is longer) prior to randomisation.

13. Previously participated in a clinical trial within 4 weeks prior to randomisation.

14. In the opinion of the (sub) investigator, the subject is unlikely to comply with the clinical trial protocol (e.g. due to alcoholism, drug addiction or psychotic state).

15. Females who are pregnant, or of child-bearing potential and wish to become pregnant during the trial, or who are breast-feeding.

16. Females of child-bearing potential with a positive urine pregnancy test at visit 1.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Xamiol® gel

Daivonex® scalp solution


Locations

Country Name City State
China The Second Affiliated hospital Zhejiang University School of Medicine Hangzhou Zhejiang

Sponsors (2)

Lead Sponsor Collaborator
LEO Pharma Tigermed Consulting Co., Ltd

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary safety of Xamiol® gel (adverse events) To establish the safety of Xamiol® gel over a long period for up to 28 weeks of treatment in Chinese subjects. Incidence of adverse drug reactions of any type and Incidence of adverse events of concern associated with long-term corticosteroid use on the scalp. 28 Weeks
Secondary Efficacy of Xamiol® gel ( percentage of visits in which subjects had "Treatment success" according to Investigator's Global Assessment) To establish the efficacy of Xamiol® gel over a long period for up to 28 weeks of treatment in Chinese subjects. The percentage of visits in which subjects had "Treatment success" according to Investigator's Global Assessment of disease severity during the treatment. The percentage of visits in which subjects had "Treatment success" according to subject's global assessment of disease severity during the treatment. 28 Weeks
See also
  Status Clinical Trial Phase
Completed NCT03669757 - Clinical Trial to Assess Safety, Tolerability and the Pharmacodynamic Effect of Different Concentrations of a New Anti-inflammatory Substance in Subjects With Chronic Plaque Psoriasis Phase 1
Completed NCT03614078 - A Study of PRCL-02 in Moderate to Severe Chronic Plaque Psoriasis Phase 2
Completed NCT03584360 - Role of Topical Treatments in the Modulation of Skin Microbiome in Psoriatic Skin Phase 2
Recruiting NCT04994951 - Pilot Study of Traditional Chinese Medicine (Qing-Re-Liang-Xue Decoction) as Complementary Medicine for Psoriasis Vulgaris of Blood-heat Syndrome. Phase 2
Completed NCT02888236 - LEO 32731 for the Treatment of Moderate to Severe Psoriasis Vulgaris Phase 2
Completed NCT02193815 - A 12 Day Study To Evaluate A Topical Drug To Treat Plaque Psoriasis Phase 1
Completed NCT02004847 - Blue Light for Treating Psoriasis Vulgaris N/A
Completed NCT01946386 - A Vasoconstriction Study With LEO 90100 Phase 1
Recruiting NCT01443338 - Study Evaluating the Efficacy and Safety of Triptergium Wilfordii and Acitretin in Psoriasis Vulgaris - CHINA201002016-2 Phase 4
Completed NCT01188928 - LEO 80185 in the Treatment of Psoriasis Vulgaris on the Non-scalp Regions of the Body (Trunk and/or Limbs) Phase 3
Completed NCT00764751 - Efficacy and Safety of LEO 19123 Cream in the Treatment of Psoriasis Vulgaris Phase 2
Completed NCT00236171 - Evaluation of Topical Antipsoriatics in the Psoriasis Plaque Test N/A
Completed NCT04541329 - Predicting Inflammatory Skin Disease Response to IL-23 Blockade Phase 4
Completed NCT06064084 - Incretin Effect in Patients With Psoriasis and Controls
Not yet recruiting NCT06398106 - Proactive TDM Versus Standard Use of Biologics in Psoriasis Phase 4
Recruiting NCT05390515 - Psoriatic Immune Response to Tildrakizumab Phase 4
Recruiting NCT05892640 - Low-Salt Diet Effect on Th17-Mediated Inflammation and Vascular Reactivity in Psoriasis N/A
Recruiting NCT04950218 - The Psoriasis Echo Study
Completed NCT05184348 - Plexin B2 Gene Expression and Polymorphisms in Psoriasis Phase 1
Recruiting NCT04394936 - An Explorative Psoriasis Biomarker Study N/A